- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00706121
S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 (ACP)
S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT
RATIONALE: Studying tissue samples in the laboratory from participants receiving treatment on the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SWOG-S0000 may help doctors predict a participant's response to treatment and help plan the best treatment.
PURPOSE: This phase III trial is studying the effect of vitamin E and/or selenium on colorectal polyps in men enrolled on SELECT Trial SWOG-S0000.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- To assess the effect of selenium on colorectal adenoma (CRA) occurrence.
- To assess the effect of selenium on number, location, size, histologic type, and degree of dysplasia of CRA.
- To assess the effect of selenium on colorectal cancer (CRC) incidence.
Secondary
- To assess the effect of vitamin E on CRA occurrence.
- To assess the effect of vitamin E on CRC incidence.
Tertiary
- To explore the effect modification of selenium and vitamin E by aspirin on CRA occurrence.
- To explore the effect modification of selenium and vitamin E by body mass index.
OUTLINE: This is a multicenter study.
Endoscopically obtained tissue samples are reviewed by study pathologists to confirm the presence (or absence) of a colorectal adenoma (CRA). If a CRA is present, the number, location, size, histology, and degree of dysplasia are documented. The CRA is also reviewed to exclude a diagnosis of colorectal cancer.
Additional data, including aspirin use, height and weight, date of birth, and other demographic and baseline characteristics, is also obtained. Participants' medical records are reviewed periodically.
Participants are followed annually.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 86724
- Arizona Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
- Enrolled on the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SWOG-S0000
- Screened by lower endoscopy (i.e., sigmoidoscopy and/or colonoscopy) after randomization on SELECT trial
PATIENT CHARACTERISTICS:
- Willing to sign an applicable medical records release form
- Willing to allow the release of tissue for central pathology review of resected polyps and endoscopic biopsies
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Vitamin E + selenium placebo
Vitamin E and selenium placebo daily for 7 - 12 years
|
400 IU daily by mouth for 7 - 12 years
Outros nomes:
1 pill by mouth daily for 7 - 12 years
Outros nomes:
|
|
Experimental: Selenium + vitamin E placebo
Selenium and vitamin E placebo daily for 7 - 12 years
|
200 mcg daily for 7 - 12 years
Outros nomes:
1 pill by mouth daily for 7 - 12 years
Outros nomes:
|
|
Experimental: Vitamin E + selenium
Vitamin E and selenium daily for 7 - 12 years
|
400 IU daily by mouth for 7 - 12 years
Outros nomes:
200 mcg daily for 7 - 12 years
Outros nomes:
|
|
Comparador de Placebo: Vitamin E placebo + selenium placebo
Vitamin E placebo and selenium placebo daily for 7 - 12 years
|
1 pill by mouth daily for 7 - 12 years
Outros nomes:
1 pill by mouth daily for 7 - 12 years
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
|
|
Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo
Prazo: From 1 year post randomization through study completion
|
Adenomas with diameter >=1cm or any adenoma with villous features or high-grade dysplasia
|
From 1 year post randomization through study completion
|
|
Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
|
|
Effect of Selenium on Occurrences of Multiple (>2) Adenomas
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Effect of Vitamin E on CRA Occurrence, Analyzed by Active Vitamin E vs. Vitamin E Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
Outras medidas de resultado
Medida de resultado |
Prazo |
|---|---|
|
Effect Modification of Selenium by Body Mass Index on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
|
Effect Modification of Selenium by Aspirin on CRA Occurrence, Analyzed by Active Selenium vs. Selenium Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
|
Effect Modification of Vitamin E by Body Mass Index on CRA Occurence, Analyzed by Active Vitamin e vs. Vitamin e Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
|
Effect Modification of Vitamin E by Aspirin on CRA Occurrence, Analyzed by Active Vitamin e vs. Vitamin e Placebo
Prazo: From 1 year post randomization through study completion
|
From 1 year post randomization through study completion
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CDR0000593329
- U10CA037429 (Concessão/Contrato do NIH dos EUA)
- S0000D (Outro identificador: SWOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .